Lixte Biotechnology Holdings Inc — Cash Flow (NASDAQ:LIXT)

Financials

Cash from operating activities 2.13 M-4.14 M-4.61 M-4.29 M-3.16 M -2.58 M Cash from investing activities ————— — Cash from financing activities 4.6 M3.9 M5.14 M3.14 M0 6.47 M Free cash flow 2.13 M-4.14 M-4.61 M-4.29 M-3.16 M -2.58 M

ニュース

LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary

LIXTE expands clinical trial for ovarian cancer treatment

リクステ・バイオテクノロジー株、4.3百万ドルの直接募集後に下落

スパータン・キャピタル、リクステ・バイオテクノロジーの430万ドル調達で引受役を務める

Lixte Biotechnology stock falls after $4.3 million direct offering

Spartan Capital acts as placement agent in Lixte’s $4.3 million offering

リクステ・バイオテクノロジーの株価、4300万ドルの直接募集後に下落

Lixte Biotechnology stock falls after $4.3 million direct offering

Lixte Biotechnology raises $4.3 million in registered direct offering

リクステ・バイオテクノロジーの株主、取締役候補と株式計画改正を承認

Lixte Biotechnology shareholders approve board nominees and stock plan amendment

リクステ・バイオテクノロジー株、英国リオラ社買収後に下落